STTK
Shattuck Labs, Inc. [STTK] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
STTK Stock Summary
Top 10 Correlated ETFs
STTK
Top 10 Correlated Stocks
STTK
In the News
Shattuck Labs, Inc. (STTK) Q4 2022 Earnings Call Transcript
Shattuck Labs, Inc. (NASDAQ:STTK ) Q4 2022 Earnings Conference Call February 23, 2023 4:45 PM ET Company Participants Conor Richardson - Vice President, Investor Relations Taylor Schreiber - Chief Executive Officer and Scientific Co-Founder Lini Pandite - Chief Medical Officer Andrew Neill - Chief Financial Officer Conference Call Participants Jonathan Miller - Evercore ISI Marc Frahm - Cowen Yigal Nochomovitz - Citi Zhiqiang Shu - Berenberg Operator Good afternoon, ladies and gentlemen. Welcome to the Shattuck Labs Fourth Quarter and Full Year 2022 Earnings Conference Call.
Shattuck Labs to Report Fourth-Quarter and Full-Year 2022 Financial Results on February 23, 2023
AUSTIN, TX & DURHAM, NC, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will report its fourth quarter and full year 2022 financial results and provide a general business overview on Thursday, February 23, 2023.
Shattuck Labs, Inc. (STTK) Q3 2022 Earnings Call Transcript
Shattuck Labs, Inc. (NASDAQ:STTK ) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Conor Richardson - Senior Director of Finance and Investor Relations Taylor Schreiber - Chief Executive Officer Lini Pandite - Chief Medical Officer Andrew Neill - Chief Financial Officer Conference Call Participants Marc Frahm - Cowen Gil Blum - Needham & Company Carly Kenselaar - Citi Kaveri Pohlman - BTIG Zhiqiang Shu - Berenberg Operator Good afternoon, everyone, and welcome to Shattuck Labs Third Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Shattuck Labs to Report Third Quarter 2022 Financial Results on November 8, 2022
AUSTIN, TX and DURHAM, NC, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will report third quarter 2022 financial results and provide a general business overview on Tuesday, November 8, 2022.
Shattuck Labs to Present Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting November 8-12
AUSTIN, TX & DURHAM, NC, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will present a poster on its bispecific Gamma Delta T Cell Engager (GADLEN) platform at SITC's 37th Annual Meeting being held November 8th – 12th, 2022, virtually and in-person in Boston.
Should You Buy Shattuck Labs (STTK) Ahead of Earnings?
Shattuck Labs (STTK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Why Earnings Season Could Be Great for Shattuck Labs (STTK)
Shattuck Labs (STTK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Shattuck Labs to Present Two Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting
AUSTIN, Texas and DURHAM, N.C., March 09, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that two posters have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting, which is being held April 8-13, 2022 at the Ernest N. Morial Convention Center in New Orleans, Louisiana. The first poster will highlight preclinical data from the company's GADLEN™ platform, while the second will highlight preclinical data from SL-9258 (TIGIT-Fc-LIGHT), derived from the company's ARC® platform, demonstrating its ability to broaden the activity of checkpoint inhibitors through targeted myeloid cell and effector lymphocyte activation.
Shattuck Labs Announces Participation in Upcoming 11th Annual SVB Leerink Global Healthcare Conference
AUSTIN, TX and DURHAM, NC, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK ), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease with three ongoing Phase 1 clinical trials, today announced that company management will participate in the 11th Annual SVB Leerink Global Healthcare Conference being held February 14-18, 2022.
Shattuck Labs Announces Participation in Upcoming January Investor Conferences
AUSTIN, TX and DURHAM, NC, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease with three ongoing Phase 1 clinical trials, today announced that company management will participate in two virtual investor conferences in January 2022.
STTK Financial details
STTK Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 1.49 | 0.66 | 0.64 | 0 | 0.02 | |
| Net income per share | -0.49 | -1.59 | -2.36 | 0 | -2.41 | |
| Operating cash flow per share | -0.46 | -1.39 | -2.17 | -1.35 | 0 | |
| Free cash flow per share | -0.54 | -1.43 | -2.22 | -1.35 | 0 | |
| Cash per share | 4.01 | 2.6 | 21.63 | 6.38 | 3.81 | |
| Book value per share | -0.74 | -2.3 | 19.98 | 6.45 | 4.16 | |
| Tangible book value per share | -0.74 | -2.3 | 19.98 | 6.45 | 4.16 | |
| Share holders equity per share | -0.74 | -2.3 | 19.98 | 6.45 | 4.16 | |
| Interest debt per share | 0.17 | 0 | 0 | 0 | 0.1 | |
| Market cap | 291.1M | 291.1M | 812.67M | 358.75M | 97.47M | |
| Enterprise value | 259.46M | 284.09M | 654.77M | 266.48M | 54.29M | |
| P/E ratio | -39.4 | -12.14 | -22.2 | 0 | -0.96 | |
| Price to sales ratio | 12.97 | 29.44 | 81.81 | 0 | 149.5 | |
| POCF ratio | -42.17 | -13.88 | -24.14 | -6.28 | -1.03M | |
| PFCF ratio | -36.02 | -13.57 | -23.63 | -6.28 | -918.57K | |
| P/B Ratio | -26.27 | -8.43 | 2.62 | 1.32 | 0.55 | |
| PTB ratio | -26.27 | -8.43 | 2.62 | 1.32 | 0.55 | |
| EV to sales | 11.56 | 28.73 | 65.91 | 0 | 83.27 | |
| Enterprise value over EBITDA | -57.63 | -12.12 | -18.2 | -5.89 | -0.53 | |
| EV to operating cash flow | -37.59 | -13.54 | -19.45 | -4.67 | -574.56K | |
| EV to free cash flow | -32.11 | -13.25 | -19.04 | -4.67 | -511.67K | |
| Earnings yield | -0.03 | -0.08 | -0.05 | 0 | -1.05 | |
| Free cash flow yield | -0.03 | -0.07 | -0.04 | -0.16 | 0 | |
| Debt to equity | -7.15 | -2.3 | 0.13 | 0.1 | 0.17 | |
| Debt to assets | 1.16 | 1.77 | 0.11 | 0.09 | 0.14 | |
| Net debt to EBITDA | 7.03 | 0.3 | 4.39 | 2.04 | 0.42 | |
| Current ratio | 3.15 | 2.12 | 20.53 | 0 | 7.39 | |
| Interest coverage | -2.34 | 0 | 0 | 0 | 0 | |
| Income quality | 0.93 | 0.87 | 0.92 | 0 | 0.93 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.17 | 0.58 | 0.94 | 0 | 32.33 | |
| Research and developement to revenue | 1.11 | 2.96 | 3.77 | 0 | 127.15 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.17 | 0.02 | 0.02 | 0 | 0.12 | |
| Capex to revenue | -0.05 | -0.05 | -0.07 | 0 | 0 | |
| Capex to depreciation | -4.62 | -0.88 | -1.18 | 0 | -2.61 | |
| Stock based compensation to revenue | 0.02 | 0.05 | 0.13 | 0 | 0 | |
| Graham number | 2.85 | 9.08 | 32.58 | 0 | 15 | |
| ROIC | -2.18 | -0.9 | -1.17 | -0.4 | -1 | |
| Return on tangible assets | -0.11 | -0.53 | -0.1 | 0 | -0.5 | |
| Graham Net | -1.25 | -2.69 | 19.11 | 5.74 | 3.12 | |
| Working capital | 44.78M | 22.46M | 328.81M | 288.27M | 159.62M | |
| Tangible asset value | -11.08M | -34.55M | 309.86M | 271.79M | 176.16M | |
| Net current asset value | -13.61M | -37.08M | 306.51M | 261.47M | 155.42M | |
| Invested capital | 0 | 0 | 0 | 0 | 0.02 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 2.55M | 2.4M | 877K | 3.59M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0.67 | 0.69 | -0.12 | 0 | -0.58 | |
| Capex per share | -0.08 | -0.03 | -0.05 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2022-12-31 for Q4
| Metric | History | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 0.71 | 0 | 0 | 0.01 | 0.01 | |
| Net income per share | 0 | -0.58 | -0.65 | -0.58 | -0.6 | |
| Operating cash flow per share | -0.44 | -0.62 | -0.38 | -0.66 | 1.67 | |
| Free cash flow per share | -0.3 | -0.68 | -0.57 | -0.68 | 1.92 | |
| Cash per share | 2.18 | 5.65 | 5.06 | 4.37 | 3.81 | |
| Book value per share | 6.43 | 5.88 | 5.25 | 4.7 | 4.16 | |
| Tangible book value per share | 6.43 | 5.88 | 5.25 | 4.7 | 4.16 | |
| Share holders equity per share | 6.43 | 5.88 | 5.25 | 4.7 | 4.16 | |
| Interest debt per share | 0.03 | 0.11 | 0.11 | 0.1 | 0.1 | |
| Market cap | 359.86M | 180.44M | 172.06M | 114.44M | 97.47M | |
| Enterprise value | 267.59M | 134.44M | 138.76M | 79.07M | 54.29M | |
| P/E ratio | 0 | -1.84 | -1.57 | -1.16 | -0.96 | |
| Price to sales ratio | 11.96 | 0 | 3.44K | 539.83 | 249.93 | |
| POCF ratio | -19.23 | -6.87 | -10.55 | -4.08 | 1.38 | |
| PFCF ratio | -28.16 | -6.27 | -7.17 | -3.97 | 1.19 | |
| P/B Ratio | 1.32 | 0.72 | 0.77 | 0.57 | 0.55 | |
| PTB ratio | 1.32 | 0.72 | 0.77 | 0.57 | 0.55 | |
| EV to sales | 8.9 | 0 | 2.78K | 372.98 | 139.22 | |
| Enterprise value over EBITDA | 0 | -5.59 | -5.2 | -3.34 | -1.98 | |
| EV to operating cash flow | -14.3 | -5.12 | -8.5 | -2.82 | 0.77 | |
| EV to free cash flow | -20.94 | -4.67 | -5.78 | -2.74 | 0.67 | |
| Earnings yield | 0 | -0.14 | -0.16 | -0.22 | -0.26 | |
| Free cash flow yield | -0.04 | -0.16 | -0.14 | -0.25 | 0.84 | |
| Debt to equity | 0.1 | 0.09 | 0.13 | 0.12 | 0.17 | |
| Debt to assets | 0.09 | 0.08 | 0.11 | 0.11 | 0.14 | |
| Net debt to EBITDA | 0 | 1.91 | 1.25 | 1.49 | 1.57 | |
| Current ratio | 0 | 15.17 | 9.46 | 10.53 | 7.39 | |
| Interest coverage | 7 | 0 | 0 | 0 | 0 | |
| Income quality | 0 | 1.07 | 0.6 | 1.14 | 0.92 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 94.9 | 31.03 | 12.25 | |
| Research and developement to revenue | 0 | 0 | 459.26 | 88.97 | 56.12 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0.09 | 0.47 | 0.03 | 0.15 | |
| Capex to revenue | 0 | 0 | -153.66 | -3.54 | 28 | |
| Capex to depreciation | 0 | -5.27 | -11.61 | -0.8 | -5.28 | |
| Stock based compensation to revenue | 0 | 0 | 30.66 | 8.13 | -12.23 | |
| Graham number | 0 | 8.75 | 8.74 | 7.84 | 7.49 | |
| ROIC | 0 | -0.15 | -0.16 | -0.18 | -0.25 | |
| Return on tangible assets | 0 | -0.09 | -0.11 | -0.11 | -0.12 | |
| Graham Net | 1.55 | 5.14 | 4.38 | 3.81 | 3.12 | |
| Working capital | 288.27M | 238.17M | 205.17M | 182.38M | 159.62M | |
| Tangible asset value | 271.79M | 248.94M | 222.53M | 199.42M | 176.16M | |
| Net current asset value | 261.47M | 233.44M | 200.61M | 177.99M | 155.42M | |
| Invested capital | 0 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 1.63M | 1.3M | 4.13M | 4.36M | 5.1M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0 | -0.1 | -0.12 | -0.12 | -0.14 | |
| Capex per share | 0 | -0.06 | -0.18 | -0.02 | 0.26 |
STTK Frequently Asked Questions
What is Shattuck Labs, Inc. stock symbol ?
Shattuck Labs, Inc. is a US stock , located in Austin of Tx and trading under the symbol STTK
What is Shattuck Labs, Inc. stock quote today ?
Shattuck Labs, Inc. stock price is $3.03 today.
Is Shattuck Labs, Inc. stock public?
Yes, Shattuck Labs, Inc. is a publicly traded company.
Company Profile
- Volume Average 45.06K
- Market Capitalization 128.62M
- Employee 85
- CEO Dr. Taylor H. Schreiber M.D., Ph.D.
- Headquarters Austin,TX,US
- IPO Date 2020-10-09
-
Website
https://www.shattucklabs.com 
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
